drugset / Trial / NCT07483346
IASO-782 in Systemic Lupus Erythematosus
RandomizedParallel-groupQuadruple-blindTreatment
Summary
his study is a randomized, double-blinded, and placebo-controlled phase Ia clinical study in subjects with SLE. The study is designed to assess the safety and tolerability of IASO-782 for the treatment of SLE.
Timeline
- Start
- 2026-04-30
- Primary completion
- 2027-08-31
- Completion
- 2028-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IASO-782 | Unknown | 4 mg/kg | Intravenous |
| Subject | IASO-782 | Unknown | 6 mg/kg | Intravenous |
| Subject | IASO-782 | Unknown | 10 mg/kg | Intravenous |